Cargando…
Ovarian cancer treatment: The end of empiricism?
The diagnosis, investigation, and management of ovarian cancer are in a state of flux—balancing ever rapid advances in our understanding of its biology with 3 decades of clinical trials. Clinical trials that started with empirically driven selections have evolved in an evidence‐informed manner to gr...
Autores principales: | Lheureux, Stephanie, Karakasis, Katherine, Kohn, Elise C., Oza, Amit M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744728/ https://www.ncbi.nlm.nih.gov/pubmed/26096019 http://dx.doi.org/10.1002/cncr.29481 |
Ejemplares similares
-
Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention
por: Karakasis, Katherine, et al.
Publicado: (2016) -
Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations
por: Madariaga, Ainhoa, et al.
Publicado: (2019) -
Measuring Quality of Life in Ovarian Cancer Clinical Trials—Can We Improve Objectivity and Cross Trial Comparisons?
por: Bhat, Gita, et al.
Publicado: (2020) -
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020) -
Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery
por: Colombo, Ilaria, et al.
Publicado: (2023)